Review/Update on Thymic Malignancy and Mesothelioma

Thymic malignancies and mesothelioma are rare cancers that require complex multidisciplinary management. There have been recent advances in the management of these cancers including the integration of PD-L1 immunotherapy, major surgical trials and consensus statements that have aimed to improve standard of care. It is important to disseminate these advances in care to improve patient outcomes for these rare tumors.

This will be a multidisciplinary session focusing on the management of mesothelioma and thymic carcinoma. Surgical discussion will include technical considerations for the multidisciplinary team and recently presented trials such as MARS-2. There will be discussion on the indications for radiation in management as well as technological improvements like particle therapy that might offer opportunities to improve the therapeutic ratio. In terms of systemic therapy, the historic cytotoxic backbones will be presented as well as advances based upon an understanding of disease biology such as PD-L1 directed immune therapy.

Target Audience

This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pulmonologists.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Understand advances in systemic management of mesothelioma and thymic malignancies such as the integration of PD-L1 immune therapy.
  • Understand impact of surgery for mesothelioma from recent trials and surgical considerations for thymic malignancies.
  • Understand indications for radiation and improvements in radiation technology such as particle therapy.
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
12/03/2023
Course expires: 
12/02/2025
Cost:
$0.00
Part of: 
2023 Multidisciplinary Thoracic Cancers Symposium onDemand
Rating: 
0

Moderator:

  • Stephen Chun, MD

Speakers:

  • Andrea Wolf, MD
  • Quymh-Nhu Nguyen, MD
  • Matthew Gubens, MD, MS

 

Faculty:
A list of all meeting faculty and Individual presenter disclosures are linked to their names in the Schedule of Events.

Planning Committee:
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee website page.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.